A Novel Gene Delivery Vector of Agonistic Anti-Radioprotective 105 Expressed on Cell Membranes Shows Adjuvant Effect for DNA Immunization Against Influenza.
Adjuvants, Immunologic
/ genetics
Animals
Antibodies, Monoclonal
/ genetics
Antigens, CD
/ genetics
Antigens, Surface
/ genetics
B-Lymphocytes
/ drug effects
Cell Membrane
/ drug effects
Cell Proliferation
/ drug effects
Coculture Techniques
Gene Transfer Techniques
Genetic Vectors
HEK293 Cells
Hemagglutinin Glycoproteins, Influenza Virus
/ genetics
Humans
Hybridomas
Immunization
Influenza Vaccines
/ genetics
Lymphocyte Activation
/ drug effects
Membrane Glycoproteins
/ genetics
Mice, Inbred BALB C
Mice, Knockout
Orthomyxoviridae Infections
/ immunology
Rats
Receptors, IgG
/ genetics
Spleen
/ drug effects
Vaccines, DNA
/ pharmacology
DNA immunization
RP105
adjuvant
agonistic antibody
antibody gene-vector delivery
cell membrane
influenza
targeting antigen to B cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
09
2020
accepted:
18
11
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Radioprotective 105 (RP105) (also termed CD180) is an orphan and unconventional Toll-like receptor (TLR) that lacks an intracellular signaling domain. The agonistic anti-RP105 monoclonal antibody (mAb) can cross-link RP105 on B cells, resulting in the proliferation and activation of B cells. Anti-RP105 mAb also has a potent adjuvant effect, providing higher levels of antigen-specific antibodies compared to alum. However, adjuvanticity is required for the covalent link between anti-RP105 mAb and the antigen. This is a possible obstacle to immunization due to the link between anti-RP105 mAb and some antigens, especially multi-transmembrane proteins. We have previously succeeded in inducing rapid and potent recombinant mAbs in mice using antibody gene-based delivery. To simplify the covalent link between anti-RP105 mAb and antigens, we generated genetic constructs of recombinant anti-RP105 mAb (αRP105) bound to the transmembrane domain of the IgG-B cell receptor (TM) (αRP105-TM), which could enable the anti-RP105 mAb to link the antigen
Identifiants
pubmed: 33414788
doi: 10.3389/fimmu.2020.606518
pmc: PMC7783388
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antibodies, Monoclonal
0
Antigens, CD
0
Antigens, Surface
0
H1N1 virus hemagglutinin
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Influenza Vaccines
0
Ly78 protein, mouse
0
Ly86 protein, mouse
0
Membrane Glycoproteins
0
Receptors, IgG
0
Vaccines, DNA
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
606518Informations de copyright
Copyright © 2020 Yamazaki, Biswas, Kosugi, Nagashima, Inui, Tomono, Takagi, Ichimonji, Nagaoka, Ainai, Hasegawa, Chiba and Akashi-Takamura.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Transl Med. 2020 Mar 17;18(1):131
pubmed: 32183811
J Exp Med. 2013 Sep 23;210(10):2135-46
pubmed: 24019553
Sci STKE. 2000 Aug 08;2000(44):re1
pubmed: 11752602
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
J Exp Clin Cancer Res. 2019 Apr 5;38(1):146
pubmed: 30953535
J Immunol. 2004 Mar 1;172(5):3280-8
pubmed: 14978136
Vaccine. 2000 Aug 1;18(28):3214-22
pubmed: 10869766
Methods Enzymol. 2020;635:139-148
pubmed: 32122542
J Gene Med. 2004 May;6(5):584-92
pubmed: 15133769
Arch Immunol Ther Exp (Warsz). 2010 Jun;58(3):209-25
pubmed: 20458549
J Exp Med. 2010 May 10;207(5):1113-24
pubmed: 20404103
Nature. 2011 Nov 30;481(7379):81-4
pubmed: 22139420
Vaccine. 1994 Dec;12(16):1499-502
pubmed: 7879413
Biochem Biophys Res Commun. 2008 Feb 8;366(2):445-9
pubmed: 18067856
Trends Immunol. 2007 Nov;28(11):482-90
pubmed: 17964218
Nat Rev Drug Discov. 2018 Mar;17(3):197-223
pubmed: 29192287
J Immunol. 1998 Aug 1;161(3):1348-53
pubmed: 9686597
Virology. 2008 Aug 15;378(1):79-85
pubmed: 18556039
Immunol Rev. 2010 Sep;237(1):205-25
pubmed: 20727038
J Virol. 2020 Feb 28;94(6):
pubmed: 31852790
Int J Mol Med. 2005 Oct;16(4):683-8
pubmed: 16142405
J Gastroenterol Hepatol. 2009 Feb;24(2):262-9
pubmed: 19032461
Gene Ther. 2000 Aug;7(15):1344-9
pubmed: 10918507
J Immunol Methods. 1982 Dec 30;55(3):319-26
pubmed: 6762397
Vaccines (Basel). 2018 Jun 26;6(3):
pubmed: 29949942
Nat Immunol. 2005 Jun;6(6):571-8
pubmed: 15852007
PLoS One. 2013 May 21;8(5):e63247
pubmed: 23704898
J Immunol. 2019 Oct 1;203(7):1715-1729
pubmed: 31484732
J Immunol. 2005 Jun 1;174(11):7043-9
pubmed: 15905547
Nat Med. 2020 Mar;26(3):430-440
pubmed: 32066977
Int Immunol. 2012 Jun;24(6):389-400
pubmed: 22354914
J Immunol. 2006 Nov 15;177(10):7435-43
pubmed: 17082663
Sci Rep. 2015 Jul 29;5:12616
pubmed: 26220099
Vaccines (Basel). 2020 Jul 29;8(3):
pubmed: 32751206
J Immunol Methods. 2012 Jan 31;375(1-2):243-51
pubmed: 22123185
J Immunol Methods. 1987 Jun 26;100(1-2):123-30
pubmed: 3598193
Front Immunol. 2018 Jan 24;9:47
pubmed: 29416543
Gene Ther. 1999 Jul;6(7):1258-66
pubmed: 10455434
Nat Med. 2011 Jul 17;17(8):996-1002
pubmed: 21765404
J Med Virol. 2010 Mar;82(3):476-84
pubmed: 20087927
J Immunol. 2020 Apr 15;204(8):2133-2142
pubmed: 32188759
Clin Cancer Res. 2020 Feb 1;26(3):598-607
pubmed: 31582519
Hum Vaccin. 2009 Aug;5(8):568-71
pubmed: 19736511
Nat Biotechnol. 2005 May;23(5):584-90
pubmed: 15834403
Nat Methods. 2019 Feb;16(2):183-190
pubmed: 30700903
Theranostics. 2019 Jan 1;9(1):210-231
pubmed: 30662563
J Immunol. 2011 Oct 15;187(8):4199-209
pubmed: 21918197
Methods Enzymol. 1986;121:386-411
pubmed: 2941671
Jpn J Infect Dis. 2011;64(1):40-9
pubmed: 21266754
PLoS Pathog. 2017 Nov 27;13(11):e1006743
pubmed: 29176765
Hum Antibodies. 2006;15(4):139-54
pubmed: 17522436
J Biol Chem. 2019 Apr 26;294(17):6659-6669
pubmed: 30833330
J Gene Med. 2018 May;20(5):e3015
pubmed: 29575374
J Immunol. 2011 Sep 15;187(6):3438-47
pubmed: 21841127
PLoS One. 2017 Feb 27;12(2):e0172791
pubmed: 28241049
J Exp Med. 1994 Oct 1;180(4):1217-24
pubmed: 7523567
J Pharmacol Toxicol Methods. 2011 May-Jun;63(3):250-7
pubmed: 21184834
J Immunol. 1995 Apr 1;154(7):3333-40
pubmed: 7897216
J Microbiol Methods. 2001 Nov;47(2):135-49
pubmed: 11576678
Nat Immunol. 2003 Sep;4(9):815
pubmed: 12942076
Emerg Microbes Infect. 2016 Apr 06;5:e33
pubmed: 27048742
Int J Mol Sci. 2019 Dec 06;20(24):
pubmed: 31817576
Microb Pathog. 2006 Aug-Sep;41(2-3):49-58
pubmed: 16782300
J Immunol. 1992 Aug 1;149(3):981-8
pubmed: 1634780
J Leukoc Biol. 2017 Jan;101(1):183-192
pubmed: 27067450
Int Immunol. 2016 Oct;28(10):503-512
pubmed: 27352793
Nihon Ika Daigaku Zasshi. 1986 Oct;53(5):534-6
pubmed: 3536992
Blood. 2002 Mar 1;99(5):1699-705
pubmed: 11861286
Immunol Lett. 2015 Dec;168(2):349-54
pubmed: 26551033
PLoS One. 2017 Oct 12;12(10):e0185967
pubmed: 29023479